Dov Goldstein

Dov Goldstein is the current Chief Financial Officer at BioAge. Prior to joining BioAge, Goldstein served as the Chief Financial Officer and Chief Business Offer at Indapta Therapeutics from August 2020 to November 2021. From January 2020 to June 2021, they were a Director at RIGImmune. From November 2017 to May 2018, Goldstein was the CFO at Schrodinger Therapeutics. Dov also served as a Director at ADMA Biologics, Inc. from May 2008 to November 2019 and Esperion - The Lipid Management Company from May 2008 to May 2019. Goldstein was a Partner at Aisling Capital from September 2006 to November 2019. Prior to that, they served as the CFO at Vicuron Pharmaceuticals from July 2000 to November 2005. Goldstein began their career as the Director of Venture Analysis at HealthCare Ventures LLC from August 1998 to July 2000.

Dov Goldstein graduated from Stanford University with a Bachelor of Science in Biology/Biological Sciences, General. Dov then attended Yale School of Medicine and earned their Doctor of Medicine. Finally, they completed their Master of Business Administration at Columbia Business School in Finance, General.

They are on a team with Rusty Montgomery - VP, Biology, Peng Leong - Chief Business Officer, and Chris Patil - VP, Media. and Ralph Scarborough - VP, Finance & Accounting reports to Dov Goldstein. Their manager is Kristen Fortney, Co-Founder & CEO.